BiotechTube
Oncostellae

Oncostellae

Barcelona, Spain· Est.
oncostellae.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Oncostellae is a Spanish biotechnology startup developing innovative, small-molecule therapeutics for oncology and inflammatory/autoimmune diseases. Its strategy centers on creating novel chemical scaffolds targeting clinically validated pathways, with a lead program, OST-122, demonstrating promising Phase 2a proof-of-concept in ulcerative colitis. The company operates a capital-efficient model, advancing programs to clinical proof-of-concept before out-licensing to pharmaceutical partners for late-stage development and commercialization.

OncologyImmunologyInflammatory DiseasesAutoimmune DiseasesFibrosis

Technology Platform

Expertise in medicinal chemistry and pharmacology for designing novel small-molecule scaffolds (NCEs) targeting clinically validated pathways, with a focus on improving safety via targeted delivery (e.g., gut-restricted action) and novel mechanism modulation.

Opportunities

The lead program, OST-122, addresses a multi-billion dollar IBD market with a potentially best-in-class safety profile as a gut-restricted JAK inhibitor.
The company's capital-efficient partnership model allows it to reach key clinical milestones without the massive funding required for late-stage trials, positioning it for lucrative out-licensing deals.

Risk Factors

The company faces significant clinical risk as its promising Phase 2a data for OST-122 requires validation in larger trials.
It operates in highly competitive therapeutic areas (JAK inhibition, fibrosis) and is reliant on securing partnership deals to fund later-stage development, introducing execution and financing risk.

Competitive Landscape

In IBD, OST-122 competes with numerous systemic JAK inhibitors (e.g., Pfizer's Xeljanz, AbbVie's Rinvoq) and a growing pipeline of gut-selective candidates. In uterine fibroids, it faces competition from other medical therapies and procedural interventions. Its novel ARK5 inhibitor for fibrosis enters a crowded but high-reward field with many large pharma players.

More companies in Small Molecule Drugs →More companies in Spain →